Background Data on the effectiveness and safety of rivaroxaban for the treatment of patients
with venous thromboembolism (VTE) and active cancer are limited in the Japanese real …

Objective The purpose of this study is to evaluate the efficacy and safety of rivaroxaban in
patients with venous thromboembolism and active malignancy, given the paucity of clinical …

Abstract Background: Venous thromboembolism (VTE), consisting of deep vein thrombosis
(DVT) and pulmonary embolism (PE), is a common complication of both cancer and its …

Background Low molecular weight heparin (LMWH) is the guideline endorsed treatment of
choice for cancer associated venous thromboembolism (VTE). Rivaroxaban offers a …

Background Rivaroxaban could be an attractive alternative to low molecular weight heparin
for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and …

Background Direct-acting oral anticoagulants (DOACs) are alternatives to low molecular
weight heparin (LMWH) in most cancer-associated thrombosis (CAT) patients. Objectives …

Background Primary and recurrent venous thromboembolism (VTE) commonly occur in
patients with cancer. However, because of the National Health Insurance regulations …

Low-molecular weight heparin (LMWH) has been the standard of care for treatment of
venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 …

Introduction Patients with active cancer have a high risk for venous thromboembolism (VTE).
The current treatment of choice for cancer-associated thrombosis is low molecular weight …

In this issue, Coleman et al 1 report on their study, a retrospective cohort analysis of 3,708
patients with cancer and venous thromboembolism (VTE) from the OSCAR-US …